Lymphodepleting fludarabine + cyclophosphamide conditioning before idecabtagene vicleucel (ide-cel) CAR-T
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-FLUDARABINE DRUG-CYCLOPHOSPHAMIDE |
|---|
| ID | REG-IDECEL-LYMPHODEPLETION-FLU-CY |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-KARMMA-MUNSHI-2021 SRC-NCCN-MM-2025 |
Notes
Lymphodepleting conditioning phase for ide-cel (idecabtagene vicleucel, REG-IDECEL-MM-3L). Standardized in KarMMa pivotal phase-2 trial (Munshi NEJM 2021): fludarabine 30 mg/m² + cyclophosphamide 300 mg/m² IV daily × 3 days, days -5 to -3. Distinct from the 500 mg/m² Cy regimen used with axi-cel / brexu-cel — ide-cel pivotal trial used 300 mg/m². Single course immediately preceding CAR-T infusion; no maintenance. Coordinated administration before the CAR-T centre receives the patient. STUB — pending Co-Lead sign-off.
Used By
No reverse references found in the YAML corpus.